JAVASCRIPT DISABLED - This site works best with JavaScript enabled.

FDA Clearance of Faster Interpretation Time of Chromogenic MRSASelect™

Bio-Rad now have FDA clearance for a faster interpretation time of its existing MRSASelect™ test, a chromogenic medium that is used for the rapid screening of MRSA (methicillin-resistant Staphylococcus aureus).

With high sensitivity and specificity as well as rapid and direct identification, the MRSASelect test can now identify MRSA carriers in as little as 18 hours. Bio-Rad received FDA clearance in the U.S. to market its MRSASelect test with the new interpretation time in June. The test was originally introduced in the U.S. in October 2007.

NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source : Bio-Rad Laboratories View Company Information

Posted on September 16, 2008